Colombo M.,Fondazione Istituto Nazionale Dei Tumori |
Blok M.J.,Maastricht University |
Whiley P.,QIMR Berghofer Medical Research Institute |
Whiley P.,University of Queensland |
And 26 more authors.
Human Molecular Genetics
Loss-of-function germline mutationsin BRCA1(MIM#113705) confer markedly increased risk of breastandovarian cancer. The full-lengthtranscript codifies for a protein involved in DNA repair pathways and cell-cycle checkpoints. Several BRCA1 splicing isoformshavebeendescribed in publicdomaindatabases, but thephysiological role (if any) of BRCA1 alternative splicing remains to be established.Anaccurate description of 'naturally occurring' alternative splicing at this locus is a prerequisite to understand its biological significance. However, a systematic analysis of alternative splicing at the BRCA1 locus is yet to be conducted. Here, the Evidence-Based Network for the Interpretation of Germ-Line Mutant Alleles consortium combines RT-PCR, exon scanning, cloning, sequencing and relativesemi-quantificationto describe naturally occurring BRCA1 alternative splicing with unprecedented resolution. The study has been conducted in blood-related RNA sources, commonly used for clinical splicing assays, as well as in one healthy breast tissue. We have characterized a total of 63 BRCA1 alternative splicing events, including 35 novel findings. A minimum of 10 splicing events (D1Aq, D5, D5q, D8p, D9, D(9, 10), D9_11, D11q, D13p and D14p) represent a substantial fraction of the full-length expression level (rangingfrom5to100%). Remarkably,ourdata indicate that BRCA1 alternative splicing is similar inbloodandbreast, a finding supporting the clinical relevance of blood-based in vitro splicing assays. Overall, our data suggest an alternative splicing model in which most non-mutually exclusive alternative splicing events are randomly combined into individual mRNA molecules to produce hundreds of different BRCA1 isoforms. © The Author 2014.Published by Oxford University Press. All rights reserved. Source